Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Immunotherapy in advanced gastric cancer, is it the future?

Coutzac C, Pernot S, Chaput N, Zaanan A.

Crit Rev Oncol Hematol. 2019 Jan;133:25-32. doi: 10.1016/j.critrevonc.2018.10.007. Epub 2018 Nov 2. Review.

PMID:
30661655
2.

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.

Charrier M, Mezquita L, Lueza B, Dupraz L, Planchard D, Remon J, Caramella C, Cassard L, Boselli L, Reiners KS, Pogge von Strandmann E, Rusakiewicz S, Ferrara R, Duchemann B, Naigeon M, Pignon JP, Besse B, Chaput N.

Eur J Cancer. 2019 Feb;108:88-96. doi: 10.1016/j.ejca.2018.12.017. Epub 2019 Jan 14.

PMID:
30648633
3.

Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.

Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R.

Eur J Cancer. 2019 Jan;106:144-159. doi: 10.1016/j.ejca.2018.11.002. Epub 2018 Dec 5. Review.

PMID:
30528799
4.

Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.

Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F.

Nat Commun. 2018 Nov 30;9(1):5097. doi: 10.1038/s41467-018-07603-1.

5.

Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.

de Malet A, Antoni G, Collins M, Soularue E, Marthey L, Vaysse T, Coutzac C, Chaput N, Mateus C, Robert C, Carbonnel F.

Eur J Cancer. 2019 Jan;106:106-114. doi: 10.1016/j.ejca.2018.10.006. Epub 2018 Nov 23.

PMID:
30476730
6.

Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?

Nebot-Bral L, Coutzac C, Kannouche PL, Chaput N.

Bull Cancer. 2019 Feb;106(2):105-113. doi: 10.1016/j.bulcan.2018.08.007. Epub 2018 Oct 17. Review.

PMID:
30342749
7.

Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses.

Pitoiset F, Cassard L, El Soufi K, Boselli L, Grivel J, Roux A, Klatzmann D, Chaput N, Rosenzwajg M.

Cytometry A. 2018 Aug;93(8):793-802. doi: 10.1002/cyto.a.23570. Epub 2018 Aug 31.

PMID:
30168890
8.

Enterocolitis due to immune checkpoint inhibitors: a systematic review.

Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F.

Gut. 2018 Nov;67(11):2056-2067. doi: 10.1136/gutjnl-2018-316948. Epub 2018 Aug 21. Review.

PMID:
30131322
9.

Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting.

Asvatourian V, Coutzac C, Chaput N, Robert C, Michiels S, Lanoy E.

BMC Med Res Methodol. 2018 Jul 3;18(1):67. doi: 10.1186/s12874-018-0527-5.

10.

IL-2 antibodies in type 1 diabetes and during IL-2 therapy.

Churlaud G, Rosenzwajg M, Cacoub P, Saadoun D, Valteau-Couanet D, Chaput N, Pugliese A, Klatzmann D.

Diabetologia. 2018 Sep;61(9):2066-2068. doi: 10.1007/s00125-018-4649-4. Epub 2018 Jun 2. No abstract available.

PMID:
29860627
11.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

12.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B.

Lung Cancer. 2017 Oct;112:10-15. doi: 10.1016/j.lungcan.2017.07.004. Epub 2017 Jul 29.

PMID:
29191581
13.

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.

Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F.

Ann Oncol. 2017 Nov 1;28(11):2860-2865. doi: 10.1093/annonc/mdx403.

PMID:
29045560
14.

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.

Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N.

J Crohns Colitis. 2017 Oct 1;11(10):1238-1246. doi: 10.1093/ecco-jcc/jjx081.

PMID:
28967957
15.

Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?

Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B.

Cancer Treat Rev. 2017 Nov;60:60-68. doi: 10.1016/j.ctrv.2017.08.003. Epub 2017 Aug 24. Review.

16.

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.

Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Chaput N, Kannouche PL.

Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29. Review.

PMID:
28846956
17.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F.

Ann Oncol. 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108.

PMID:
28368458
18.

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Carbonnel F, Soularue E, Coutzac C, Chaput N, Mateus C, Lepage P, Robert C.

Semin Immunopathol. 2017 Apr;39(3):327-331. doi: 10.1007/s00281-016-0613-x. Epub 2017 Jan 16. Review.

PMID:
28093620
19.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C.

Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.

20.

IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.

Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, Wijdenes J, Adotévi O, Ferrand C, Romero P, Godet Y, Borg C.

J Immunol. 2016 Jul 1;197(1):85-96. doi: 10.4049/jimmunol.1501147. Epub 2016 May 27.

21.

IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.

Desbois M, Le Vu P, Coutzac C, Marcheteau E, Béal C, Terme M, Gey A, Morisseau S, Teppaz G, Boselli L, Jacques Y, Béchard D, Tartour E, Cassard L, Chaput N.

J Immunol. 2016 Jul 1;197(1):168-78. doi: 10.4049/jimmunol.1600019. Epub 2016 May 23.

22.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N.

Oncoimmunology. 2015 Aug 12;5(4):e1071008. eCollection 2016 Apr.

23.

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.

Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F.

J Crohns Colitis. 2016 Apr;10(4):395-401. doi: 10.1093/ecco-jcc/jjv227. Epub 2016 Jan 18.

24.

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.

Remon J, Chaput N, Planchard D.

Curr Opin Oncol. 2016 Mar;28(2):122-9. doi: 10.1097/CCO.0000000000000263. Review.

PMID:
26756384
25.

Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.

Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, Chaput N, Chatterjee D, Court FA, Del Portillo HA, O'Driscoll L, Fais S, Falcon-Perez JM, Felderhoff-Mueser U, Fraile L, Gho YS, Görgens A, Gupta RC, Hendrix A, Hermann DM, Hill AF, Hochberg F, Horn PA, de Kleijn D, Kordelas L, Kramer BW, Krämer-Albers EM, Laner-Plamberger S, Laitinen S, Leonardi T, Lorenowicz MJ, Lim SK, Lötvall J, Maguire CA, Marcilla A, Nazarenko I, Ochiya T, Patel T, Pedersen S, Pocsfalvi G, Pluchino S, Quesenberry P, Reischl IG, Rivera FJ, Sanzenbacher R, Schallmoser K, Slaper-Cortenbach I, Strunk D, Tonn T, Vader P, van Balkom BW, Wauben M, Andaloussi SE, Théry C, Rohde E, Giebel B.

J Extracell Vesicles. 2015 Dec 31;4:30087. doi: 10.3402/jev.v4.30087. eCollection 2015.

26.

Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer.

Chaput N, Marabelle A.

Eur Respir J. 2015 Dec;46(6):1541-3. doi: 10.1183/13993003.01595-2015. No abstract available.

27.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

28.

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.

Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G, Valteau-Couanet D, Zitvogel L.

Sci Transl Med. 2015 Apr 15;7(283):283ra55. doi: 10.1126/scitranslmed.aaa2327.

PMID:
25877893
29.

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L.

Cell Res. 2015 Mar;25(3):399-400. doi: 10.1038/cr.2015.28. No abstract available.

30.

[Breaking immune tolerance in cancer].

Desbois M, Champiat S, Chaput N.

Bull Cancer. 2015 Jan;102(1):34-52. doi: 10.1016/j.bulcan.2014.12.002. Epub 2015 Jan 13. Review. French.

PMID:
25609492
31.

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L.

Cell Res. 2015 Feb;25(2):208-24. doi: 10.1038/cr.2015.3. Epub 2015 Jan 13. Erratum in: Cell Res. 2015 Mar;25(3):399-400. Zörnig, Inka [added]; Hassel, Jessica [added].

32.

Dendritic cell-derived exosomes as immunotherapies in the fight against cancer.

Pitt JM, Charrier M, Viaud S, André F, Besse B, Chaput N, Zitvogel L.

J Immunol. 2014 Aug 1;193(3):1006-11. doi: 10.4049/jimmunol.1400703. Review.

33.

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.

Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, Caignard A, Messaoudene M, Aupérin A, Vielh P, Dessen P, Porta C, Mateus C, Ayyoub M, Valmori D, Eggermont A, Robert C, Zitvogel L.

Cancer Res. 2014 Jan 1;74(1):68-80. doi: 10.1158/0008-5472.CAN-13-1186. Epub 2013 Nov 6.

34.

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer.

Chaput N, Svrcek M, Aupérin A, Locher C, Drusch F, Malka D, Taïeb J, Goéré D, Ducreux M, Boige V.

Br J Cancer. 2013 Aug 20;109(4):1013-22. doi: 10.1038/bjc.2013.362. Epub 2013 Jul 18.

35.

Potent immunomodulatory effects of the trifunctional antibody catumaxomab.

Goéré D, Flament C, Rusakiewicz S, Poirier-Colame V, Kepp O, Martins I, Pesquet J, Eggermont A, Elias D, Chaput N, Zitvogel L.

Cancer Res. 2013 Aug 1;73(15):4663-73. doi: 10.1158/0008-5472.CAN-12-4460. Epub 2013 Jun 4.

36.

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.

Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jäger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L.

Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16.

37.

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.

Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C, Zitvogel L.

Oncoimmunology. 2013 Feb 1;2(2):e23080.

38.

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.

Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A.

Oncoimmunology. 2013 Feb 1;2(2):e23079.

39.

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.

Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C.

Ann Oncol. 2013 Jun;24(6):1697-703. doi: 10.1093/annonc/mdt027. Epub 2013 Feb 24.

PMID:
23439861
40.

Natural killer cells in non-hematopoietic malignancies.

Desbois M, Rusakiewicz S, Locher C, Zitvogel L, Chaput N.

Front Immunol. 2012 Dec 24;3:395. doi: 10.3389/fimmu.2012.00395. eCollection 2012.

41.

Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.

Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, Chen L, Mécheri S, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Degli-Esposti M, Chaput N, Zitvogel L.

Cancer Res. 2012 Jun 1;72(11):2757-67. doi: 10.1158/0008-5472.CAN-11-3379. Epub 2012 Mar 16.

42.

Human CD90 identifies Th17/Tc17 T cell subsets that are depleted in HIV-infected patients.

Guillot-Delost M, Le Gouvello S, Mesel-Lemoine M, Cheraï M, Baillou C, Simon A, Levy Y, Weiss L, Louafi S, Chaput N, Berrehar F, Kerbrat S, Klatzmann D, Lemoine FM.

J Immunol. 2012 Feb 1;188(3):981-91. doi: 10.4049/jimmunol.1101592. Epub 2011 Dec 19.

43.

IL-18 induces PD-1-dependent immunosuppression in cancer.

Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N, Zitvogel L.

Cancer Res. 2011 Aug 15;71(16):5393-9. doi: 10.1158/0008-5472.CAN-11-0993. Epub 2011 Jul 1.

44.

acDCs enhance human antigen-specific T-cell responses.

Martinuzzi E, Afonso G, Gagnerault MC, Naselli G, Mittag D, Combadière B, Boitard C, Chaput N, Zitvogel L, Harrison LC, Mallone R.

Blood. 2011 Aug 25;118(8):2128-37. doi: 10.1182/blood-2010-12-326231. Epub 2011 Jun 28.

45.

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.

Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L.

Semin Immunopathol. 2011 Jul;33(4):369-83. doi: 10.1007/s00281-011-0245-0. Epub 2011 May 25. Review.

PMID:
21611872
46.

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Römer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Gutierrez JC, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, Vivier E, Lecesne A, Kroemer G, Zitvogel L.

Nat Med. 2011 Jun;17(6):700-7. doi: 10.1038/nm.2366. Epub 2011 May 8.

PMID:
21552268
47.

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G, Zitvogel L.

J Exp Med. 2011 Mar 14;208(3):491-503. doi: 10.1084/jem.20100269. Epub 2011 Mar 7. Erratum in: J Exp Med. 2011 Apr 11:208(4):869.

48.

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Zoubir M, Flament C, Gdoura A, Bahleda R, Litvinova E, Soumelis V, Conforti R, Viaud S, Soria JC, Kroemer G, Zitvogel L, Chaput N.

Cell Cycle. 2011 Jan 1;10(1):118-26. Epub 2011 Jan 1.

PMID:
21200142
49.

Exosomes: immune properties and potential clinical implementations.

Chaput N, Théry C.

Semin Immunopathol. 2011 Sep;33(5):419-40. doi: 10.1007/s00281-010-0233-9. Epub 2010 Dec 21. Review.

PMID:
21174094
50.

Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ.

Viaud S, Ploix S, Lapierre V, Théry C, Commere PH, Tramalloni D, Gorrichon K, Virault-Rocroy P, Tursz T, Lantz O, Zitvogel L, Chaput N.

J Immunother. 2011 Jan;34(1):65-75. doi: 10.1097/CJI.0b013e3181fe535b.

PMID:
21150714

Supplemental Content

Loading ...
Support Center